Showing results (1-10 of 1,250) with videos related to

Sort By:
Pageof 125
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscapeK A Olaussen, S Postel-Vinay
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonismD Morel, G Almouzni, J-C Soria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2018
Epigenetic modifiers as new immunomodulatory therapies in solid tumoursS Aspeslagh, D Morel, J-C Soria, et al.
Bulletin Du Cancer|January 12, 2011
[Dose finding methods for targeted agents: new perspectives]X Paoletti, S Postel-Vinay, V Servois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodiesS Postel-Vinay, S Aspeslagh, E Lanoy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?S Postel-Vinay, Y Boursin, C Massard, et al.
British Journal of Cancer|April 30, 2009
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?S Postel-Vinay, H-T Arkenau, D Olmos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR studyT André, C Tournigand, L Mineur, et al.
Oncogene|August 13, 2013
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancerS Postel-Vinay, I Bajrami, L Friboulet, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2014
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committeeR Califano, M V Karamouzis, S Banerjee, et al.
Pageof 125